Importance of Growth Factors and Bone Maturation Ratio in the Response to Growth Hormone Therapy
Authors' conclusion
Low pretreatment IGF-1, a greater BA delay with respect to CA pretreatment and at the onset of puberty, a greater increase in IGFBP-3 after 2 years of treatment, and a lower increase in BA and BA/CA ratio after 1 and 2 years of treatment imply a better long-term response.
Study context
- Population
- Patients treated with GH for idiopathic GHD
- Participants
- 139 patients
- Outcome
- Response to GH therapy: adult height (AH), AH vs target height, vs initial height prognosis, vs height at start of treatment and vs height at onset of puberty
- Follow-up
- After 1 and 2 years of treatment and at final height
Methodological detailslongitudinal, observational
- Longitudinal
- Observational
Main finding
As reported in the abstract
Associations of IGF-1, IGFBP-3 and BA/CA ratio with response to GH therapy
- Lower pretreatment IGF-1 → better response
- r = −0.405, P = .007
- Greater increase in IGF-1 at end of treatment → better response
- r = 0.274, P = .014
- Greater increase in IGFBP-3 after 2 years of treatment → better response
- r = 0.207, P = .035
- Greater increase in IGFBP-3 at end of treatment → better response
- r = 0.259, P = .020
- Lower bone age (BA)/chronological age (CA) ratio pretreatment → better response
- r = −0.502, P = .000
- Lower BA/CA ratio at onset of puberty → better response
- r = −0.548, P = .000
- Lower increase in BA and BA/CA ratio after 1 year of treatment → better response
- r = −0.337, P = .000
- Lower increase in BA and BA/CA ratio after 2 years of treatment → better response
- r = −0.332, P = .000
Observational data: associations, not effects.
Original publication
Importance of Growth Factors and Bone Maturation Ratio in the Response to Growth Hormone Therapy. Endocr Pract. Published 3 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →